Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maribavir - Takeda

Next Previous
X
Search
Drug Profile

Maribavir - Takeda

Alternative Names: 1263W94; Benzimidavir; Camvia; GW 1263; GW 1263W94; LIVTENCITY; LIVTENCITYTM; Maribavir - Shire; SHP-620; TAK 620; VP41263

Latest Information Update: 26 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Takeda; ViroPharma
  • Class Antivirals; Benzimidazoles; Ribonucleosides; Small molecules
  • Mechanism of Action Ganciclovir kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cytomegalovirus infections

Most Recent Events

  • 24 Jun 2024 Registered for Cytomegalovirus infections (In adolescents, In the elderly, In adults) in Japan (PO)
  • 03 Jun 2024 Takeda plans a phase-III trial for Cytomegalovirus infections in China (PO), (NCT06439342)
  • 26 Dec 2023 Registered for Cytomegalovirus infections in China (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top